

Special Issue

Glioma Metabolism, Epigenetics, and Microenvironment

Message from the Guest Editors

Malignant gliomas represent the most common primary malignancy of the central nervous system and cause significant morbidity and mortality. Extensive characterization at the genetic level has led to the adoption of molecular parameters, for the first time, in addition to the traditional histology features in the 2016 World Health Organization (WHO) classification of the central nervous system tumors. The inclusion of molecular parameters, including hotspot mutations in *IDH1* and *H3F3A*, genetic alterations in *TP53* and *ATRX*, and chromosomal 1p/19q codeletion, in the WHO classification considerably improves the classification of gliomas and the prediction of patient outcomes. Although the knowledge has yet to significantly improve patient outcome, recent discoveries in glioma metabolism, epigenetics, and the microenvironmental influence on cellular states and plasticity have identified tumor vulnerability and heterogeneity but have also revealed tumor complexity.

Guest Editors

Dr. L. Eric Huang

Department of Neurosurgery, University of Utah, Salt Lake City, UT, USA

Prof. Dr. Shi-Yuan Cheng

Department of Neurology, Northwestern Brain Tumor Institute, Robert H. Lurie Comprehensive Cancer Center University of Northwestern Feinberg School of Medicine, 303 East Superior, Lurie 7-119, Chicago, IL 60626, USA

Deadline for manuscript submissions

closed (31 July 2022)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/94448

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).